Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenotransplantation

This article was originally published in The Gray Sheet

Executive Summary

Recipients of xenotransplantation products "should be deferred from donation of whole blood, blood components" and other body products, according to a revision issued Oct. 18 to the 1996 Draft PHS Guidelines on Infectious Disease Issues in Xenotransplantation. The revised document, which expands the definition of xenotransplantation from "live cells, tissues, or organs from a nonhuman animal source" to include "human body fluids, cells, tissues or organs that have had ex vivo contact with live nonhuman cells, tissues, or organs," is available online (http://www.fda.gov/cber/gdlns/xenophs1000.htm)
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT014061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel